APPIA Announces 2021-2023 Officers and Directors
Erico von Bueren elected president of the Anatomical Pathology Patient Association

For Immediate Release
Contact: Claudia Carroll, ccarroll@firstpointresources.com

Raleigh, N.C. – The Anatomical Pathology Patient Association is pleased to announce the election of a slate of officers and directors for 2021-2023.

Erico von Bueren was elected to a two-year term as President, stepping into the seat previously held by Beth Sheppard, who continues to serve on the APPIA Board of Directors as Immediate Past President.

Mr. von Bueren is Director of Marketing for Sakura Finetek USA, Inc. He started his career in the pharmaceutical industry in medical, product and marketing management in several therapeutic areas and moved into the in-vitro diagnostic industry, concentrating on the fields of flow cytometry and anatomic pathology. Now at Sakura Finetek USA, his focus in commercial and global product and market development resides in automating and standardizing anatomic pathology through continuous innovation.

Other newly elected Officers and Directors are President-Elect Shalini Singh, Head of Pathology at Roche Diagnostics Solutions in Tucson, AZ, and Treasurer Doug Felten, Director of Segment Marketing for the Americas Diagnostics and Genomics Group, for Agilent Technologies, Olga Kolman, Medical Director and Pathologist for Leica Biosystems, and David Ferber, Senior Medical Science Liaison at Leica Biosystems.

Also serving on the Board are as follows:

- George Kennedy, Senior Vice President of Sales and Marketing for Sakura Finetek USA
- Angie Cahill, Senior International Product Manager in the Oncology Core Assays Lifecycle for Roche Diagnostics Solutions
- Bryce Portier, Enterprise Medical Director and Head of Medical Affairs for Agilent Technologies.

Learn more about APPIA and its Board of Directors.

About APPIA:
APPIA is a not-for-profit membership organization dedicated to the issues affecting laboratory practices, quality, and ultimately the safety of patients. In keeping with the organization's mission, to ensure accuracy and reduce variation in test results, proper validation studies are needed at the onset of clinical test implementation. However, laboratories worldwide face challenges in gathering enough tissues and cases for antigens with rare occurrence in the population or from patients with a specific rare disease to perform required verification and validation studies for new laboratory products and immunohistochemical tests.